Kornimate/medical-research-clean huggingface dataset:
evaluation of lactate in patients undergoing glial and non glial mass surgery with craniotomy

Conditions: Lactate; Brain Tumor; Post-Op Complication

Summary: the aim of this study is to determine the effects of the level of metabolites used in routine on mortality and morbidity in patients who will undergo intracranial surgery with craniotomy.

in this study, in patients who are planned to have an intracranial mass operation with craniotomy, their medical histories, demographic features, comorbidities, preoperative radiotherapy treatment, the parameters examined in the preoperative routine will be collected as a file scan (previous operations, gks, laboratory values). the classification of patients according to the 2016 world health organization central classification of nervous system tumors (who-cns classification) and whether it is glial or non glial will be recorded from the clinical file. intraoperative; hemodynamic data of patients; heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products delivered, anesthetic and other medications, and blood gas samples will be written from the anesthesia document after the operation is finished. for the study, the application of the anesthesiologist for the patient will not be interfered. if postoperative patients are sent to the intensive care unit, their laboratory values and clinical observations (mortality, morbidity, neurological sequelae, imaging techniques, gose (glasgow outcome skale)) will be recorded. in our study, mortality and morbidity will be evaluated 30 days postoperatively, and if the patient was sent to the service from the intensive care unit in this process, the values in the postoperative clinic (mortality, morbidity, neurological evaluation, imaging techniques, pathology results) will be recorded from the patient document. if the patient was discharged 30 days before, outpatient data will be recorded. the patients will be classified by evaluating the collected data (intraoperative hemodynamic data, blood transfusions, postoperative neurological sequel, postoperative complications and mortality). in our study; the effects of lactate level on mortality and morbidity will be investigated in patients undergoing an intracranial mass operation with general anesthesia.

Eligibility criteria:
inclusion criteria: 1. having an intracranial mass operation with craniotomy 2. no history of congestive heart failure 3. no kidney and liver dysfunction 4. not pregnant 5. not taking inotropic drugs during the operation 6. receiving less than four red blood product replacements during the operation exclusion criteria: 1. patients with a history of congestive heart failure 2. patients with kidney and liver dysfunction 3. patients who need an inotropic agent to adjust blood pressure during the operation 4. patients who have undergone four or more red blood product transfusions during the operation 5. pregnant patients

Keywords: lactate glial and non glial tumor intracranial craniotomy
parentification among children whose parents cope with a serious mental illness

Conditions: Mental Illness

Summary: the research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life. this research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population. the differences between these two populations with regard to parentification, quality of life, social support and fairness will also be examined. the parents and the children will fill out questionnaires. the research group will be recruited from rehabilitation services, mental health clinics, psychiatric hospitals and social welfare departments with sampling method. the comparison group will be recruited from schools. this research broadens the knowledge of the causes and the repercussions of parentification among children of parents who struggles with serious mental illness in comparison with children raised by parents from a non-clinical population. few studies have examined children of the mentally ill in israel, and there are none which examined parentification.


Eligibility criteria:
inclusion criteria: * children who live with at least one parent who struggles with serious mental illness exclusion criteria: * arabic children

Keywords: children of mentally ill
cervarix long-term safety surveillance

Conditions: Infections, Papillomavirus

Summary: this study aims to assess whether the use of cervarix® is associated with a modified risk of central demyelination, type 1 diabetes (dt1), cutaneous lupus, inflammatory arthritis, idiopathic thrombocytopenic purpura (itp), lupus erythematosus, myositis and dermatomyositis, guillain-barre syndrome and/or autoimmune thyroiditis and graves disease by using the pgrx information system.

pgrx is an information system that intends to bridge the resource gap to assess the effect of a drug on the risk of adverse events that are infrequent and/or with a long delay of onset. it uses some characteristics of the ad hoc case-control or case-referent design, transposed on a prospective, on-going, population-based recruitment plan. this particular design is called here systematic case-referent design in contrast to the ad hoc case-control or case-referent methodology. the pgrx information system is based on the routine and targeted recruitment of cases of a series of pathologies, compared to population-based referents for the study of exposure to a wide variety of drugs. drug exposure ascertainment is obtained from two different sources in the pgrx. system: a) a structured patient interview (telephone-administered questionnaire) b) the medical data form with the computerized medical prescriptions (interview guide)

Eligibility criteria:
inclusion criteria: * male and female * age 14 to 79 years-old (included) * patient residing in france * patient accepting to participate in the study * patient can read and respond to a telephone interview exclusion criteria: * prior reported history of the disease * patient or patient's parent cannot read the interview guide or answer a telephone interview questionnaire in french * refusal to participate

Keywords: autoimmune diseases (aids) cervarix pgrx information system
drug reactions sampling (collectiontoxidermies)

Conditions: Stevens-Johnson Syndrome; Lyell Syndrome; Drug Reactions; AGEP; DRESS; Bullous Dermatosis Caused by Drug Treatment (Disorder); Maculopapular Exanthem; Erythema Multiforme

Summary: intro: dermatology department of henri mondor hospital (creteil, france), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (stevens-johnson syndrome (sjs), lyell syndrome (toxic epidermal necrolysis (ten)), generalized bullous fixed drug reactions, agep, dress, drug induced immunoglobulin a (iga) bullous dermatosis, and erythema multiforme). in order to conduct clinical and biological research studies in drug reactions, it is necessary for the investigator's department to implement a collection of clinical data and biological samples. hypothesis/objective: to collect clinical data and cutaneous and biological samples for immunological, biological and genetic studies to improve knowledge about pathophysiology of drug reactions. method: the following samples will be performed in addition to the routine practice samples: one skin punch biopsy (6mm); 43 ml of blood; blister fluid aspiration; oral and nose mucous membrane and skin eswabs, stool samples. these samples will be stored in a dedicated biological sampling department ("platform of biological resources"). conclusion: the implementation of this collection should allow us to conduct pathophysiological studies about drug reactions.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 y-old * severe cutaneous drug reaction (agep, dress, sjs/ten, generalized bullous fixed drug eruption), drug-induced iga bullous dermatosis, maculopapular exanthema, erythema multiforme * signed consent * social security affiliation exclusion criteria: * patients law protection

Keywords: drug reactions severe cutaneous adverse reactions (scars stevens-johnson syndrome lyell syndrome (generalized bullous) fixed drug reaction agep dress drug induced iga bullous dermatosis maculopapular exanthema erythema multiforme sampling collection
birth defects associated with exposure to lamotrigine in pregnancy (eurocat)

Conditions: Epilepsy

Summary: in 2007 a case control study was completed within the eurocat european network of congenital anomaly registers to test the hypothesis that first trimester lamotrigine monotherapy exposure is associated with an increased risk of isolated oral clefts. this study found no statistically significant increased risk of oral clefts compared with other defects following lamotrigine exposure in the uterus. the eurocat antiepileptic drug (aed) database, established for the original case control study in 2007, will now be expanded to include an additional five to six years worth of data. these data will provide greater power to investigate the risk of isolated oral clefts, specific cleft types and potential associations with additional specific malformation types (e.g. neural tube defects). data on cases of isolated oral clefts registered between 1993 and 2012 will be extracted from eurocat member registers meeting set inclusion criteria (ensuring completeness of outcome and exposure data). the primary comparison group will include all non oral cleft, non chromosomal malformations as the registers do not collect data on non malformed infants. this study will also be powered to include a second control group of chromosomal malformations, very unlikely to be associated with medication exposure. data on exposure to anti-epileptic drugs (aeds) during the first trimester of pregnancy will be extracted along with other key covariates including age of mother, history of epilepsy and gestational age of the infant. primary analyses, using logistic regression, will compare the lamotrigine monotherapy versus no aed use across case and control groups and a secondary analysis will compare lamotrigine monotherapy versus other aed monotherapy (with and without valproate). data will also be monitored for patterns of lamotrigine exposure across additional specific malformation groups of interest.


Eligibility criteria:
inclusion criteria: * individual population-based registers within eurocat are eligible to participate if: * anti-epileptic drug exposure is recorded for at least 3 per 1000 malformed infants/fetuses (figures below this threshold indicate potential under reporting of medication exposure). * specific drug names or complete 7 digit anatomical therapeutic chemical (atc) classification codes are available for at least 80% of aed exposed infants/fetuses. exclusion criteria: * as above

Keywords: isolated oral clefts lamotrigine eurocat congenital malformations anti-epileptic drugs
quantification of dopamine active transporter (dat) in humans: validation of a new radiophamaceutical, the [18f] lbt-999

Conditions: Idiopathic Parkinson Disease

Summary: idiopathic parkinson's disease (ipd) is a degenerative disease affecting the dopaminergic system. clinical symptoms of ipd commonly begin after the loss of at least 40 to 50% of striatal dopaminergic terminals (specially putaminal terminals). the dopamine neuronal transporter (dat) is a highly expressed protein in the membrane of presynaptic nigrostriatal dopaminergic terminals. the use of a dat's radioligand in the initial stages of the disease would lead to an early detection of nigral cell loss. currently, only one dat's radioligand has obtained marketing authorization in france, the 123i-fpcit, for use in single photon emission computed tomography (spect). otherwise, the positron emission tomography (pet), a more sensitive technology than spect with higher resolution has become for a few years the new gold standard for visual analysis and quantification of neurotransmission systems (including the dopaminergic system). a dat tracer labelled with carbon 11 (\[11c\] pe2l) have been developed and is currently used as a reference in various research centers. however, in order to enable a clinical use of this tracer (which currently can't be because of the too short period of carbon 11), the unit inserm u930 "imaging and brain" in collaboration with the cerrp (center for studies and research on radiopharmaceuticals) developed a new version of this tracer, labelled with 18-fluor: the \[18f\] lbt-999. the main goal of this study is to compare the \[18f\] lbt-999 uptake between a group of patients suffering from a parkinsonien syndrome to a group healthy volunteers.


Eligibility criteria:
inclusion criteria: criteria common to all participants: * age between 45 and 75 years old * signed informed consent * affiliated to a social security system criteria for patients: * idiopathic parkinson's disease according to the ukpdsbb criteria * stage 1-3 hoen and yahr (unilateral disease to moderate or mild bilateral disease in a self patient ) criteria for healthy volunteers: * matching according to age (± 5 years) exclusion criteria: criteria common to all participants: * history of taking an antipsychotic or any other drug with a dopaminergic effect in the previous 6 months * contraindications to mri * person with severe claustrophobia * patient with a legal protection measure * alcohol or drug abuse history (in the past 10 years) * history of progressive disease that can affect the central nervous system (blood pressure greater than or equal to 180/100 mmhg, chronic lung disease with hypoxia, heart failure stage 4) * all medical and surgical affection older than 3 months * history of stroke * history of head trauma (coma\> 24h) * mms\<24 * pregnancy or lactating woman without reliable contraception
pancytopenia related to parp inhibitors (pancytorib)

Conditions: Cancer

Summary: although parp inhibitors (parpi) have proved effective in treating many cancers, few patients receiving parpi may experience rare but serious adverse events such as pancytopenia. today, data about pancytopenia are scarce. the objective was to investigate reports of pancytopenia adverse events related to parpi, including olaparib, rucaparib, niraparib, talazoparib, veliparib and pamiparib using the world health organization's (who) pharmacovigilance database: vigibase.

here, investigators use the world health organization's (who) database of individual safety case reports, to identify cases of pancytopenia related to parpi.

Eligibility criteria:
inclusion criteria: * case reported in the world health organization (who) database (vigibase) of individual safety case reports at the time of the extraction, * patients treated with at least 1 parpi (with atc classification system): olaparib (atc l01xx46), niraparib (atc l01xx54), rucaparib (atc l01xx55), talazoparib (atc l01xx60), veliparib (none) and pamiparib (none). exclusion criteria: chronology not compatible between the parpi and adverse event.
orelabrutinib combined with rituximab and chemotherapy for relapsed/refractory b-cell lymphoma patients with central nervous system involvement

Conditions: CNS Lymphoma

Summary: this single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing orelabrutinib on the basis of rituximab and chemotherapy in treating patients with relapsed or refractory b-cell lymphoma invloving central nervous system.

participants will receive orelabrutinib in addition to second-line therapy consisting of rituximab and recommended chemotherapy according to histopathologic type. after treatment of 6 cycles with the new regimen, the patients achieving cr or pr would go on to receive autologous haematopoietic stem cell transplantation (auto-hsct) with or without orelabrutinib maintenance of 2 years (if tolerable) or orelabrutinib maintenance alone if intolerant to auto-hsct.

Eligibility criteria:
inclusion criteria: * 14 to 80 years old; * histopathologically confirmed cd20 positive b-cell lymphoma according to the 5th edition of the world health organization (who) classification of haematolymphoid tumours; * after systemic treatment of the cns lesions; * life expectancy of \> 3 months (in the opinion of the investigator); * no non-haematologic adverse events, except alopecia, higher than grade 1 according to common terminology criteria for adverse events (ctcae) v5.0; * absolute neutrophil count (anc) ≥ 1.0×10\^9/l, platelet count ≥ 50×10\^9/l and haemoglobin ≥ 60 g/l, without transfusion or any use of pharmacologically hematopoietic drugs in 2 weeks; * serum creatinine (scr) ≤ 1.5 times the upper limit of normal (uln) or creatinine clearance rate (ccr) ≥ 30 ml/min; * serum total bilirubin (tbil) ≤ 1.5 × uln and both aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 2.5 × uln without hepatic metastases, otherwise tbil ≤ 3 × uln and ast, alt ≤ 5 × uln respectively; * international normalized ratio (inr) ≤ 1.5 and activated partial thromboplastin time (aptt) ≤ 1.5 × uln; * left ventricular ejection fraction (lvef) ≥ 50%; * agreeing to provide written informed consent prior to any special examination or procedure for the research on their own or legal representative. exclusion criteria: * pregnant or lactating women; * known hepatitis b virus (hbv) and/or hepatitis c virus (hcv) infection (hbv infection refers to hbv-dna \> detectable limit); * with acquired or congenital immunodeficiency; * with congestive heart failure in 6 months before enrollment, new york heart association (nyha) heart function class iii or iv, or lvef \< 50%; * known to be allergic to the test drug ingredients; * diagnosed with or being treated for malignancy other than lymphoma; * with severe infection; * substance abuse, medical, psychological, or social conditions that may interfere with the subjects' participation in the study or evaluation of the study results; * deemed unsuitable for the group.

Keywords: cns lymphoma relapse refractory orelabrutinib
the effects of manual lymphatic drainage and kinesiotaping on lower extremity edema

Conditions: Total Knee Arthroplasty; Edema; Exercise

Summary: significant trauma and muscular tightness often result during total knee arthroplasty (tka) surgery and thus act to restrict tissue fluid movement resulting with lower extremity edema. kinesio taping® is applied directly on the skin for restoration of normal fluid perfusion, removing congestion of lymphatic fluid or hemorrhages. in addition manual lymphatic drainage (mld) enhances blood circulation and stimulates the lymphatic movement and unblocks lymphatic territories. the aim of the study was to investigate the effectiveness of kinesio taping® and mld in reducing postoperative edema and pain in the early stage after tka.

procedures: patients who underwent unilateral tka were randomized as kinesio taping® group, mld group and control group. for all patients, postoperative rehabilitation program included early mobilization and physical therapy twice a day during the stay in orthopedic traumatology department. on the second day after surgery, lymphatic correction method was used on the kinesio taping® group patients and a standardized 30-minute mld treatment was applied to the mld group patients. control group received only physiotherapy treatment. circumference measurements were applied on preoperatively and the second, third, fourth day and 6th weeks after surgery. knee injury and osteoarthritis outcome score (koos) was used to determine the functional outcomes on the 6th weeks after surgery. repeated measures of variance analysis was used to determine time differences between groups.

Eligibility criteria:
inclusion criteria: * tka surgery exclusion criteria: * active infection * malignant tumor * major cardiac pathology, or thrombus or venous obstruction that was pre-diagnosed or revealed on a routine preadmission hospital screening
early-access avacopan in real-world anca-associated vasculitis

Conditions: ANCA Associated Vasculitis

Summary: the current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for aav patients in europe. the study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of aav patients. by studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. these observational data can ultimately serve to address current knowledge gaps on avacopan treatment in aav patients, improve the care and drug-access for aav patients with avacopan treatment and generate new areas of research.

objective: analyse the clinical practice variation of the early access use of avacopan in real-world treated patients with anca-associated vasculitis. study design: observational cohort study study population: aav patients treated with avacopan. main study parameters/endpoints: * describe physician's treatment indications for starting avacopan * describe aav patients clinical characteristics * describe the concomitant treatment strategies employed with avacopan * describe clinical outcomes of avacopan treatment * investigate determinants of clinical benefit as well as non-response and/or relapse within the study cohort

Eligibility criteria:
inclusion criteria: * established diagnosis of gpa or mpa * treatment (initiation) with avacopan * informed consent for use of medical data exclusion criteria: * if there is no aav disease activity present that can be supported by an objectifiable clinical measure or assessment * if a subject is below 16 years old